TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 47.1

Change

-0.05 (-0.11)%

Market Cap

USD 1.81B

Volume

0.68M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+7.50 (+1.51%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

-8.89 (-1.29%)

USD 76.39B
ARGX argenx NV ADR

-10.24 (-1.73%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

-0.68 (-0.28%)

USD 31.94B
ONC BeiGene, Ltd.

+4.73 (+1.89%)

USD 28.70B
RPRX Royalty Pharma Plc

-0.17 (-0.52%)

USD 18.65B
SMMT Summit Therapeutics PLC

-0.72 (-3.62%)

USD 17.01B
UTHR United Therapeutics Corporatio..

-1.70 (-0.55%)

USD 14.37B
INCY Incyte Corporation

-0.02 (-0.03%)

USD 14.22B
MRNA Moderna Inc

-0.71 (-2.03%)

USD 13.74B

ETFs Containing TARS

XME SPDR® S&P Metals and Min.. 5.50 % 0.35 %

+0.27 (+-1.23%)

N/A
FXZ First Trust Materials Alp.. 5.17 % 0.64 %

-0.11 (-1.23%)

N/A
BASE:CA Evolve Global Materials &.. 5.09 % 0.00 %

+0.09 (+-1.23%)

CAD 0.05B
BASE-B:CA Evolve Global Materials &.. 5.09 % 0.00 %

-0.02 (-1.23%)

CAD 0.08B
SLX VanEck Steel ETF 5.08 % 0.56 %

+0.22 (+-1.23%)

N/A
PYZ Invesco DWA Basic Materia.. 3.82 % 0.60 %

-0.47 (-1.23%)

USD 0.05B
SMLL Harbor ETF Trust 3.30 % 0.28 %

-0.43 (-1.23%)

N/A
PJP Invesco Dynamic Pharmaceu.. 3.20 % 0.56 %

-0.63 (-1.23%)

N/A
PICK iShares MSCI Global Metal.. 1.57 % 0.39 %

+0.11 (+-1.23%)

USD 0.31B
SDVY First Trust SMID Cap Risi.. 1.19 % 0.60 %

-0.53 (-1.23%)

USD 8.02B
MDYV SPDR® S&P 400 Mid Cap Va.. 1.11 % 0.15 %

-0.85 (-1.23%)

N/A
IVOV Vanguard S&P Mid-Cap 400 .. 1.05 % 0.20 %

-1.02 (-1.23%)

USD 0.94B
FTA First Trust Large Cap Val.. 0.98 % 0.61 %

-0.44 (-1.23%)

USD 1.17B
SPMD SPDR Russell Small Cap Co.. 0.55 % 0.06 %

-0.81 (-1.23%)

USD 12.20B
FAB First Trust Multi Cap Val.. 0.50 % 0.70 %

-0.80 (-1.23%)

USD 0.13B
MVV ProShares Ultra MidCap400 0.46 % 0.95 %

-1.76 (-1.23%)

USD 0.15B
IWC iShares Micro-Cap ETF 0.44 % 0.60 %

-2.23 (-1.23%)

N/A
MIDU Direxion Daily Mid Cap Bu.. 0.43 % 1.10 %

-1.99 (-1.23%)

USD 0.09B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

-0.58 (-1.23%)

N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 0.00 % 0.15 %

-1.52 (-1.23%)

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

-0.21 (-1.23%)

N/A
SMLF iShares MSCI USA Small-Ca.. 0.00 % 0.30 %

-1.12 (-1.23%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

-0.53 (-1.23%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.94% 49% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.94% 49% F 33% F
Trailing 12 Months  
Capital Gain 50.24% 89% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.24% 89% A- 90% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 21.55% 67% D+ 75% C
Dividend Return 21.55% 67% D+ 74% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 67.85% 51% F 29% F
Risk Adjusted Return 31.76% 86% B+ 64% D
Market Capitalization 1.81B 87% B+ 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector